278 related articles for article (PubMed ID: 162484)
1. Activation of the alternative complement pathway.
Fearon DT
CRC Crit Rev Immunol; 1979 Nov; 1(1):1-32. PubMed ID: 162484
[No Abstract] [Full Text] [Related]
2. The alternative pathway of complement.
Pangburn MK; Müller-Eberhard HJ
Springer Semin Immunopathol; 1984; 7(2-3):163-92. PubMed ID: 6238433
[No Abstract] [Full Text] [Related]
3. Molecular biology and chemistry of the alternative pathway of complement.
Müller-Eberhard HJ; Schreiber RD
Adv Immunol; 1980; 29():1-53. PubMed ID: 6158260
[No Abstract] [Full Text] [Related]
4. [Alternative complement pathway].
Jouvin MH; Kazatchkine M
Sem Hop; 1984 May; 60(19):1371-8. PubMed ID: 6326330
[TBL] [Abstract][Full Text] [Related]
5. The binding of human complement proteins C5, factor B, beta 1H and properdin to complement fragment C3b on zymosan.
DiScipio RG
Biochem J; 1981 Dec; 199(3):485-96. PubMed ID: 6462133
[TBL] [Abstract][Full Text] [Related]
6. A circulating inhibitor of fluid-phase amplification. C3 convertase formation in systemic lupus erythematosus.
Waldo FB; Forristal J; Beischel L; West CD
J Clin Invest; 1985 Jun; 75(6):1786-95. PubMed ID: 3159752
[TBL] [Abstract][Full Text] [Related]
7. [The alternative complement pathway].
Jouvin MH; Kazatchkine M
Pathol Biol (Paris); 1983 Dec; 31(10):839-46. PubMed ID: 6230588
[TBL] [Abstract][Full Text] [Related]
8. Autoantibodies Against C3b-Functional Consequences and Disease Relevance.
Vasilev VV; Radanova M; Lazarov VJ; Dragon-Durey MA; Fremeaux-Bacchi V; Roumenina LT
Front Immunol; 2019; 10():64. PubMed ID: 30761135
[TBL] [Abstract][Full Text] [Related]
9. The properdin pathway: an "alternative activation pathway" or a "critical amplification loop" for C3 and C5 activation?
Harrison RA
Semin Immunopathol; 2018 Jan; 40(1):15-35. PubMed ID: 29167939
[TBL] [Abstract][Full Text] [Related]
10. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L
Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408
[TBL] [Abstract][Full Text] [Related]
11. Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins.
Schreiber RD; Pangburn MK; Lesavre PH; Müller-Eberhard HJ
Proc Natl Acad Sci U S A; 1978 Aug; 75(8):3948-52. PubMed ID: 279011
[TBL] [Abstract][Full Text] [Related]
12. Interaction of C3b(2)--IgG complexes with complement proteins properdin, factor B and factor H: implications for amplification.
Jelezarova E; Vogt A; Lutz HU
Biochem J; 2000 Jul; 349(Pt 1):217-23. PubMed ID: 10861231
[TBL] [Abstract][Full Text] [Related]
13. Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation.
Paixão-Cavalcante D; López-Trascasa M; Skattum L; Giclas PC; Goodship TH; de Córdoba SR; Truedsson L; Morgan BP; Harris CL
Kidney Int; 2012 Nov; 82(10):1084-92. PubMed ID: 22854646
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the interactions between properdin, the third component of complement (C3), and its physiological activation products.
Farries TC; Lachmann PJ; Harrison RA
Biochem J; 1988 May; 252(1):47-54. PubMed ID: 3421908
[TBL] [Abstract][Full Text] [Related]
15. Solubilization of immune precipitates by six isolated alternative pathway proteins.
Fujita T; Takata Y; Tamura N
J Exp Med; 1981 Dec; 154(6):1743-51. PubMed ID: 6459396
[TBL] [Abstract][Full Text] [Related]
16. Regulation of C5 convertase activity by properdin, factors B and H.
Weiler JM
Immunol Res; 1989; 8(4):305-15. PubMed ID: 2531781
[No Abstract] [Full Text] [Related]
17. Residual hemolytic and proteolytic activity expressed by Bb after decay-dissociation of C3b,Bb.
Fishelson Z; Müller-Eberhard HJ
J Immunol; 1984 Mar; 132(3):1425-9. PubMed ID: 6229580
[TBL] [Abstract][Full Text] [Related]
18. [Alternative complement pathway (author's transl)].
Kazatchkine M; Nydegger U; Fearon DT
Nouv Presse Med; 1979 Jun; 8(26):2187-94. PubMed ID: 382108
[TBL] [Abstract][Full Text] [Related]
19. Increased enzymatic activity of the alternative pathway convertase when bound to the erythrocytes of paroxysmal nocturnal hemoglobinuria.
Parker CJ; Baker PJ; Rosse WF
J Clin Invest; 1982 Feb; 69(2):337-46. PubMed ID: 6915939
[TBL] [Abstract][Full Text] [Related]
20. Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells.
Pangburn MK; Müller-Eberhard HJ
Proc Natl Acad Sci U S A; 1978 May; 75(5):2416-20. PubMed ID: 276881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
